Usability testing of Minodoronate 50mg for secondary osteoporosis in prostatic caricnoma patients

Usability testing of Minodoronate 50mg for secondary osteoporosis in prostatic caricnoma patients - Minodonate for prostatic carcinoma

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010567

Enrollment

Registered

2013-05-01

Start date

2013-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

secondary osteoporosis in prostatic carcinoma patients

Interventions

medical presence of Minodoronate

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: prostatic carcinoma patients just start hormonal treatments

Exclusion criteria

Exclusion criteria: patients using bisphosphonates patients with secondary osteoporosis which cause is not prostatic carcinoma

Design outcomes

Primary

Measure	Time frame
BMD	—

Secondary

Measure	Time frame
PSA,ICTP,BAP	—

Countries

Japan

Contacts

Public ContactIsao KURODA

Tokyo Medical University,Ibaraki Medical Center Urology

veq01625@tokyo-med.ac.jp0298871161

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026